In contrast, the levels of other factors previously reported to act protectively against diabetic cardiomyopathy, including Sirt1, Nampt, and Namnat1, were not significantly changed by the βHB treatment. The gene discussed is NAMPT; the disease is diabetic cardiomyopathy.